Screener
CRISPR Therapeutics CRSP Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Other income: | ||
| Other income, net | 8,156 | 13,537 |
| Total other income, net | 8,156 | 13,537 |
| Net loss before income taxes | (122,092) | (134,887) |
| Provision for income taxes | (839) | (1,109) |
| Net loss | (122,931) | (135,996) |
| Foreign currency translation adjustment | (32) | 41 |
| Unrealized (loss) gain on marketable securities | (6,730) | 2,254 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's pre-tax income?
- CRISPR Therapeutics (CRSP) reported pre-tax income of -$122.09M in Q1 2026.
- How has CRISPR Therapeutics's pre-tax income changed year-over-year?
- CRISPR Therapeutics's pre-tax income increased by 9.5% year-over-year, from -$134.89M to -$122.09M.
- What is the long-term trend for CRISPR Therapeutics's pre-tax income?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's pre-tax income has grown at a -5.7% compound annual growth rate (CAGR), from -$650.5M to -$577.97M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about CRISPR Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude